Herbert Irving Comprehensive Cancer Center
Investigator
Brian Henick, MD
Phone
212-305-5098
Email
bh2682@cumc.columbia.edu
Dr. Henick is a medical oncologist specializing in thoracic malignancies and experimental therapeutics. He studied Economics and health care delivery as an undergraduate at the University of Pennsylvania, and attended Rutgers-New Jersey Medical School where he was inducted to the Gold Humanism Honor Society. He completed his post-graduate training in Internal Medicine and Hematology/Medical Oncology at Yale-New Haven Hospital, where he studied the role of the innate immune system as a predictor of sensitivity or resistance to immunotherapy. He has presented his research, supported by Conquer Cancer Foundation/ASCO awards, at national conferences including ASCO. Dr. Henick’s goal as a clinician and researcher is to improve upon existing treatment strategies, personalizing each patient’s care through computational study of cancer immunobiology and by being attuned to their values and needs alongside CUMC’s dedicated multidisciplinary team.

Clinical Studies Managed By This Investigator:
Condition Study Title
Lung Cancer [ CLOSED ] Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Cancer [ CLOSED ] Study of RO7198457 in locally advanced or metastatic tumors
Solid Tumors [ CLOSED ] Study of Experimental Drug GSK3359609 in Patients with Advanced Solid Tumors
Sarcoma [ CLOSED ] Study of HuMax-AXL-ADC in Patients with Sarcoma
Cancer [ CLOSED ] Study of a Neoantigen Cancer Vaccine in Patients with Advanced Solid Tumors (Bladder, Colon, Stomach, Lung, Esophageal, or Rectal Cancer)
Lung Cancer [ CLOSED ] GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors (Non-small Cell Lung Cancer)
Solid Tumors [ CLOSED ] A Study of ASP1951 in Subjects with Advanced Solid Tumors
Lung Cancer [ CLOSED ] Radiation and Immune Checkpoints Blockade in Metastatic Non-Small Cell Lung Cancer (NSCLC)
Cancer Study of A Vaccine Targeting Shared Neoantigens in Subjects with Advanced Solid Tumors
Cancer Study of ApricityOncology Smartphone Application Monitoring and Reporting Side Effects to their Nurses and Doctors
Cancer Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)
Lung Cancer [ CLOSED ] Study of M7824 and cCRT in Patients with Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)
Lung Cancer [ CLOSED ] Study of RO7121661, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors
Lung Cancer [ CLOSED ] Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer (ARC-7)
Lung Cancer [ CLOSED ] Study of Telaglenastat in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
Lung Cancer Tomivosertib With Anti-PD-(L)1 in Subjects With Non-Small Cell Lung Cancer (NSCLC)
Cancer Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
Autoimmune Disorders Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
Cancer [ CLOSED ] Study of PF-07263689 Alone or in Combination with Sasanlimab for Patients with Advanced Cancer
Lung Cancer Liver-Directed Radiotherapy Along with Chemotherapy for Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) and Liver Metastases
Cancer Study of E-602 Alone or in Combination with Keytruda (Pembrolizumab) in Patients with Advanced Cancer
Cancer Study of BLU-222 Alone or in Combination with Other Cancer Therapy for Patients with Advanced Cancer